Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 6 | 2019 | 140 | 0.460 |
Why?
|
| Liver Neoplasms | 5 | 2018 | 159 | 0.400 |
Why?
|
| Adenocarcinoma | 5 | 2019 | 311 | 0.330 |
Why?
|
| Hepatectomy | 4 | 2018 | 64 | 0.320 |
Why?
|
| Colorectal Neoplasms | 4 | 2018 | 216 | 0.300 |
Why?
|
| Postoperative Complications | 3 | 2017 | 784 | 0.210 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 19 | 0.200 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 25 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2017 | 22 | 0.150 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 4 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 30 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 24 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 72 | 0.140 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2017 | 36 | 0.140 |
Why?
|
| Risk | 1 | 2017 | 319 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 86 | 0.130 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2004 | 10 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2279 | 0.100 |
Why?
|
| Vena Cava Filters | 1 | 1991 | 13 | 0.100 |
Why?
|
| Crohn Disease | 1 | 1991 | 26 | 0.090 |
Why?
|
| Survival Rate | 4 | 2018 | 885 | 0.090 |
Why?
|
| Hemorrhage | 1 | 1991 | 100 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 1991 | 49 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 461 | 0.090 |
Why?
|
| Aged | 10 | 2019 | 10333 | 0.090 |
Why?
|
| Humans | 15 | 2019 | 32011 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3524 | 0.070 |
Why?
|
| Male | 10 | 2019 | 19169 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 1505 | 0.070 |
Why?
|
| Middle Aged | 8 | 2017 | 11846 | 0.070 |
Why?
|
| Telomerase | 1 | 2006 | 22 | 0.070 |
Why?
|
| Camptothecin | 2 | 2005 | 52 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 55 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2005 | 68 | 0.070 |
Why?
|
| Endosonography | 1 | 2006 | 56 | 0.070 |
Why?
|
| Female | 9 | 2019 | 19930 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 262 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3314 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cystadenocarcinoma | 1 | 2004 | 3 | 0.060 |
Why?
|
| Oxyphil Cells | 1 | 2004 | 2 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2004 | 67 | 0.060 |
Why?
|
| Morbidity | 2 | 2017 | 99 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2002 | 20 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2017 | 2282 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 3998 | 0.050 |
Why?
|
| Adult | 6 | 2017 | 9356 | 0.040 |
Why?
|
| Malpractice | 1 | 2017 | 21 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 108 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 58 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 82 | 0.030 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1996 | 1 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 2637 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 142 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 185 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 240 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 271 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 3541 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 781 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 564 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1200 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 67 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1822 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1531 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 192 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 488 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 687 | 0.020 |
Why?
|
| Colectomy | 1 | 1991 | 25 | 0.020 |
Why?
|
| Hematoma | 1 | 1991 | 27 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 757 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1434 | 0.020 |
Why?
|
| Arteries | 1 | 1991 | 67 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3869 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 608 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2008 | 158 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 53 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 197 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 246 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 31 | 0.020 |
Why?
|
| Vomiting | 1 | 2005 | 24 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 53 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 43 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 77 | 0.020 |
Why?
|
| Diarrhea | 1 | 2005 | 60 | 0.020 |
Why?
|
| Fatigue | 1 | 2005 | 85 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 319 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 273 | 0.020 |
Why?
|
| Heart Failure | 1 | 1991 | 636 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 594 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 518 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2004 | 30 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 591 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 30 | 0.010 |
Why?
|
| Gallbladder Neoplasms | 1 | 2002 | 36 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 186 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 90 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 468 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 628 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1996 | 3 | 0.010 |
Why?
|
| Gastrins | 1 | 1996 | 4 | 0.010 |
Why?
|
| Somatostatin | 1 | 1996 | 11 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1996 | 45 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 144 | 0.010 |
Why?
|
| Insulin | 1 | 1996 | 366 | 0.010 |
Why?
|